Study of a CD70-targeting drug for blood cancer
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 1 study tests the safety of SEA-CD70, a drug that targets CD70, in people with certain blood cancers like MDS and AML. It may help doctors learn whether this approach can be used safely for patients whose disease has come back or not responded to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of MDS or AML (or MDS/AML) based on specific lab/blood/marrow testing
- Your cancer has relapsed or not responded (or progressed) after prior treatment with a “hypomethylating agent” such as azacitidine or similar
- You can be scored as having an ECOG performance status of 0 to 2 (0–1 is required for some groups)
- You have a measurable disease type that includes excess blasts (and for some groups, MDS-EB or AML criteria)
- You are not able to use standard options (for example, no other effective treatment options remain for your situation)
- You have no prior transplant, no prior CD70-targeted drug, and no other listed medical conditions that would make participation unsafe
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing new drug combinations for people with newly diagnosed, high-risk AML who have not yet started treatment. It aims to find more effective therapies for this aggressive form of leukemia.
This study tests a new drug (BMS-986497) alone or combined with two other medicines (azacitidine and venetoclax) for people with AML or MDS that has not responded to or returned after prior treatments. The goal is to see if this combination can help control the disease.
This Phase 1 trial tests a combination of azacitidine, venetoclax, and donor NK cells to treat acute myeloid leukemia (AML) or certain AML-like syndromes. It’s designed mainly to find safe dosing and whether this approach can control the leukemia.
This Phase 1/2 study tests how safe and tolerable EP0042 is, and looks at patients with a specific type of AML that has come back or did not respond to prior treatment. You may be considered if your AML diagnosis is confirmed and your lab tests, overall health, and medication history fit the study rules.
This trial tests a new drug, MAX-40279, combined with two standard treatments (venetoclax and azacitidine) for people with newly diagnosed acute myeloid leukemia who are not healthy enough for intensive chemotherapy. The goal is to see if adding this drug improves outcomes.
This trial tests a new drug called HC-7366 for people whose acute myeloid leukemia (AML) has come back or hasn't responded to treatment. It aims to see if this drug is safe and helpful when standard options are no longer working.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.